A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

NCT05232708 · Completed

Last updated 2026-05-28

This clinical trial compares how two different forms of semaglutide are absorbed in the body after a single dose in healthy volunteers with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 18 people

Who can join Ages 20–55 · all sexes Healthy volunteers accepted.

Timeline Started 2022-01 · est. completion 2022-08

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT05232708 ↗

Description as written by the study sponsor.

In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving into, through and out of the body when given in two separate injections. Participants will receive semaglutide B and semaglutide D in different periods of the trial (Period 1 and Period 2). Participants will receive 1 subcutaneous injection of semaglutide B (0.5 mg) and 1 subcutaneous injection of semaglutide D (0.5 mg). The trial will last for 87 to 120 days (about 3 to 4 months), depending on how long the screening period (2 to 28 days) and washout period (14 to 21 days) are. Participants will have a screening visit, followed by an in house stay (5 nights/6 days) and 9 visits for each period. Participants will have to fast for at least 6 hours overnight with only water allowed before receiving the trial medicine on the second day of in house stay (Day 1) in Period 1 and Period 2.

Treatments tested

Semaglutide B, 1.34 mg/mL Drug

Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Semaglutide D, 1.0 mg/mL Drug

Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
Semaglutide D, 1.0 mg/mL Drug

Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
Semaglutide B, 1.34 mg/mL Drug

Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

Main thing measured	AUC0-last,sema 0.5mg: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement after single dose of s.c. semaglutide 0.5 mg
Sponsor	Novo Nordisk A/S
Conditions studied	Healthy Volunteers (Diabetes Mellitus, Type 2)
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05232708 ↗